US Bancorp DE cut its stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT – Free Report) by 40.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,358 shares of the company’s stock after selling 922 shares during the period. US Bancorp DE’s holdings in PROCEPT BioRobotics were worth $109,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PRCT. Raleigh Capital Management Inc. acquired a new position in PROCEPT BioRobotics in the 4th quarter valued at $32,000. IFP Advisors Inc acquired a new position in PROCEPT BioRobotics in the 4th quarter valued at $58,000. Wilmington Savings Fund Society FSB acquired a new position in PROCEPT BioRobotics in the 3rd quarter valued at $64,000. Arcadia Investment Management Corp MI acquired a new position in PROCEPT BioRobotics in the 4th quarter valued at $64,000. Finally, Canton Hathaway LLC acquired a new position in PROCEPT BioRobotics in the 3rd quarter valued at $66,000. 89.46% of the stock is owned by institutional investors and hedge funds.
PROCEPT BioRobotics Price Performance
Shares of PRCT opened at $57.62 on Monday. PROCEPT BioRobotics Co. has a 12-month low of $45.56 and a 12-month high of $103.81. The business has a 50-day simple moving average of $70.07 and a two-hundred day simple moving average of $79.05. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. The stock has a market cap of $3.16 billion, a PE ratio of -29.55 and a beta of 1.05.
Wall Street Analyst Weigh In
Several equities analysts have weighed in on PRCT shares. Morgan Stanley dropped their price objective on PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Truist Financial reissued a “buy” rating and set a $90.00 price target (down previously from $105.00) on shares of PROCEPT BioRobotics in a report on Wednesday, February 26th. Finally, Wells Fargo & Company reissued an “overweight” rating and set a $112.00 price target on shares of PROCEPT BioRobotics in a report on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $94.29.
Check Out Our Latest Report on PROCEPT BioRobotics
PROCEPT BioRobotics Profile
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
Further Reading
- Five stocks we like better than PROCEPT BioRobotics
- What Does a Stock Split Mean?
- How to Build the Ultimate Everything ETF Portfolio
- With Risk Tolerance, One Size Does Not Fit All
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Investing In Preferred Stock vs. Common Stock
- 3 Stocks With High ROE and Market-Beating Growth Potential
Want to see what other hedge funds are holding PRCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PROCEPT BioRobotics Co. (NASDAQ:PRCT – Free Report).
Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.